Cited by 55Systemic Lupus Erythematosus ResearchVasculitis and related conditionsBlood Coagulation and Thrombosis Mechanisms

Thrombotic Risk Assessment in Systemic Lupus Erythematosus: Validation of the Global Antiphospholipid Syndrome Score in a Prospective Cohort

Open access
Sciascia, Savino, Cuadrado, Maria Jose, Sanna, Giovanni, Murru, Veronica, Roccatello, Dario, Khamashta, Munther A., Bertolaccini, Maria Laura·2014·Arthritis Care & Research

Abstract

Objective: This study was performed to prospectively and independently validate the Global Antiphospholipid Syndrome Score (GAPSS), a system derived from the combination of independent risk factors for thrombosis, including antiphospholipid antibodies (aPL) and conventional cardiovascular risk factors. Methods: The GAPSS was applied to 51 consecutive systemic lupus erythematosus patients, all positive for aPL and prospectively followed up for mean ± SD 32.94 ± 12.06 months. Of them, 48 were women with a mean ± SD age of 37.35 ± 12.15 years at entry. The GAPSS was calculated yearly for each patient by adding together the points corresponding to the risk factors. Results: An increase in the GAPSS (entry versus last visit) was seen in patients who experienced vascular events (n = 4, mean ± SD 7.5 ± 4.36 versus 10.0 ± 5.4; P = 0.032). No changes were observed in those without thrombosis (n = 47, mean ± SD 8.28 ± 4.88 versus 7.13 ± 5.75; P = 0.24). An increase in the GAPSS during the followup was associated with a higher risk of vascular events (relative risk 12.30 [95% confidence interval (95% CI) 1.43–106.13], P = 0.004), and an increase of more than 3 points showed the best risk accuracy for vascular events (hazard ratio 48 [95% CI 6.90–333.85], P = 0.0001). The cumulative proportion of thrombosis‐free individuals was lower in patients whose GAPSS was increased by 3 or more points (P = 0.0027). Conclusion: We have prospectively demonstrated that GAPSS is a valid tool for accurate prediction of vascular events in SLE patients with aPL.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/acr.22388

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The results are not directly generalizable to other patient groups included in the wide and heterogenic spectrum of APS, such as patients with SLE or patients who are positive for aCL or aβ2-GPI but not LA.

    “Consequently, our results are not directly generalizable to other patient groups included in the wide and heterogenic spectrum of APS, such as patients with SLE [34, 38] or patients who are positive for aCL or aβ2-GPI but not LA [39].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sciascia, S., Cuadrado, M. J., Sanna, G., Murru, V., Roccatello, D., Khamashta, M. A., & Bertolaccini, M. L.
Affiliations
  • King's College London (GB)
  • St Thomas' Hospital London UK
  • St Thomas' Hospital (GB)
  • University of Turin (IT)
  • King's College London UK
Venue
Arthritis Care & Research
Publisher
Wiley
Published
2014-11-24
Volume
66
Issue
12
Pages
1915-1920
ISSN
  • 0893-7524 (ISSN-L)
  • 2151-464X
  • 2151-4658
OpenAlex
W1578529971
Cited by
55
References
21
Citations by year
2025: 1 · 2024: 1 · 2023: 3 · 2022: 6 · 2021: 3 · 2020: 7 · 2019: 6 · 2018: 8 · 2017: 11 · 2016: 5 · 2015: 4
FWCI
5.53
Type
journal article
Language
en
Open access
Locations
  • Arthritis Care & Research (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • Research Portal (King's College London) (submittedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vasculitis and related conditions
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
systemic lupus erythematosus, antiphospholipid syndrome, thrombotic risk assessment, antiphospholipid antibodies, vascular events, cardiovascular risk factors, risk score validation, thrombosis prediction
MeSH terms
Adult, Female, Humans, Lupus Erythematosus, Systemic, Male, Middle Aged, Prospective Studies, Thrombosis, Antibodies, Antiphospholipid, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review